Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3 studies found for:    90Y-epratuzumab tetraxetan
Show Display Options
Rank Status Study
1 Unknown  Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Conditions: Non Hodgkin's Lymphoma;   NHL;   Aggressive NHL;   Diffuse Large B-cell Lymphoma
Interventions: Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan;   Drug: 90Y-epratuzumab tetraxetan;   Drug: veltuzumab
2 Withdrawn Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL
Condition: CD22+ Relapsed/Refractory B-ALL
Interventions: Drug: 90Y-epratuzumab tetraxetan;   Drug: chemotherapy/ immunotherapy
3 Active, not recruiting Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: 90Y-epratuzumab tetraxetan;   Biological: veltuzumab

Study has passed its completion date and status has not been verified in more than two years.